Competitive Advantages
- Significant reduction of cost and number of treatments
- Provides a more personalized treatment
- Comparatively fewer side effects
Summary
Checkpoint inhibitor therapy involves infusion of antibodies against one or more checkpoints. This therapy is expensive and has potential side effects. The invention disclosed here provides an alternative to checkpoint antibody therapy that relies on infusing proteins. This invention utilizes plasmid DNA encoding specific antigenic regions of the checkpoint. When delivered it would allow the patient to produce specific antibodies against the checkpoint as well as expressing the antigen that will complete with that checkpoint's ligand.
The figure shows the plasmids encode the soluble peptides of PD1, which may bind PDL1 on tumor cells thus blocking the interaction between PD1 and PDL1.
Desired Partnerships
- License
- Sponsored Research
- Co-Development